We would love to hear your thoughts about our site and services, please take our survey here.
05 Sep 2022
AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/
17 Jan 2023
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
24 Feb 2023 (worth viewing and listening)
Therapeutics Science Day recording and presentations
Discover pre|CISIONTM technology – delivering tumour microenvironment-targeted cancer therapies
https://avacta.com/therapeutics/
Also, two outstanding key opinion leaders in the field of oncology:
Professor Krishna Komanduri,
Professor and Chief, Division of Hematology & Oncology, UCSF Health; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center.
Dr William Tap
Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA.
700K shares traded already this morning and we are down.
Doesn’t really reflect the information shared on Science Day.
Someone looking for a lower entry point?
It's early in the day.
It's not where we start but where we finish.
GLA
Thinking about it, ….
Some less severe/embedded cancers will be cured by conventional Dox.
Patients who have a multiple cancer sites can receive Dox’ but the tolerated 6 doses may not be sufficient to kill/cure the cancer. These patients would benefit from additional doses and possibly achieve a cancer free state.
All patients receive AVA6000 but those who require additional treatments can receive these via AVA6000. That would be the ideal.
Perhaps AVA6000 can offer a cure for cancers?
GLA
@Rooba
Dr. Tap spoke about patients having Dox’ treatment(s) and surviving 18 to 24 months. Using Dox’ via AVA6000 could offer multiple treatments (18+) and therefore extend life for another 5, 10 or 20 years.
The patients reviewed were an average age of 60 so may reach 70 of 80 rather than 62.
Patients will also benefit from reduced side effects and a better quality of life.
Perhaps not a complete cure in all cases but life extending?
There was a great deal of information shared.
Think I need to have another viewing.
GLA
My understanding of comments made by Dr. William Tap as follows:
Doxorubicin (Dox’) has been used in the current form since the 1970’s. Dox’ is very good for treating cancer but the number of doses is restricted by it’s toxicity.
Dox’ does not offer a cure but extends the patient’s life. Once treatments stop, the cancer can return and can eventually result in the death of the patient. Dox’ is offering additional time but does carry side effects.
If Dox’ is targeted to the tumour(s) using AVA6000, side effects are reduced and patients can have more treatments (18+?). Additional treatments with reduced side effects will offer a life extension with much better quality of life.
Dox' via AVA6000 may not be a cure for cancer but can extend and improve quality of life.
Is that how others understood?
GLA
Took time to sit down and watch the Science Day recording yesterday.
All very positive and, if you can take the time, worth a watch.
https://avacta.com/therapeutics-science-day-recording-and-presentations/
Exciting times, both scientific & commercial, ahead.
GLA
Tue, 21st Feb 2023 07:00
RNS Number : 4842Q
Ceres Power Holdings plc
21 February 2023
Ceres' partner Weichai launches stationary power SOFC system
at ceremony to mark its CE certification with TÜV SÜD
Horsham, UK: On Saturday 18 February, Ceres' strategic partner Weichai Power, unveiled its 'world-leading high-power metal supported solid oxide fuel cell (SOFC) system' based on Ceres' technology.
In a ceremony - attended by Tan Xuguang, Chairman of Weichai Power, and Jonathan Heywood, Director of Ceres China, as part of the 11th International Conference of ICE Reliability in Jinan, China - Weichai announced that its SOFC power system using Ceres' technology has passed the EU CE certification of the international authoritative testing organisation, TÜV SÜD.
The SOFC stationary power system has been demonstrated in Weichai's Fuel Cell Industrial Park and with Weifang Energy Group, where Weichai announced it has achieved cumulative operation of more than 30,000 hours. The system can start and stop up to four times faster than other technologies, with power generation efficiency of more than 60% and cogeneration efficiency more than 85%. Installed in modular units, it can be scaled to megawatts of power output, making 'SOFC another major strategic pillar of Weichai's diversified development of energy'.
Weichai estimates that when its products reach 1GW of distributed power deployed, it has the potential to reduce carbon emissions by around two million tonnes per year, compared with electricity drawn from the grid and save around 600 million cubic metres of natural gas, compared with traditional natural gas internal combustion engine generator sets.
Weichai's press release can be read here: https://mp.weixin.qq.com/s/ASQX5TFypNwniEUmTWpG0g
February 2023 - Alastair Smith, CEO
“Cohort 4, administering more than double the normal dose of Doxorubicin”.
“Not seeing the usual Cardio-Toxicity”.
“Doxorubicin is in the tumours at significant levels”.
“It’s clear that AVA6000 can deliver a meaningful dose of Doxorubicin in to the tumour while the levels measured in the blood stream are very much lower than we would expect”.
“We are still looking for the MTD”.
“The data is unequivocal”.
It works.
Ignore the green boxes.
GLA
Alastair Smith, CEO
“Cohort 4 administering more than double the normal dose of Doxorubicin”.
“Not seeing the usual Cardio-Toxicity”.
“Doxorubicin is in the tumours at significant levels”.
“It’s clear that AVA6000 can deliver a meaningful dose of Doxorubicin in to the tumour while the
levels measured in the blood stream are very much lower than we would expect.
“We are still looking for the MTD”.
“The data is unequivocal”.
It works.
Hold & GLA
Published 3rd February 2023 and link posted by Myles (thank you) after market close at 19:34.
A very interesting read with so much positive news. A revolution in cancer treatment(s) with more positive outcomes for many. What's not to like?
It will be interesting to see how big pharma and the markets react to this latest update in the run-up the Science Day.
GLA
PROGRAMME
12:30: Lunch, Networking & Technology showcase (Molecular Sciences Research Hub)
1?3:30: Welcome & Keynotes
K?eynote: Professor Mary Ryan (Vice Provost for Research and Enterprise, Imperial College London)
K?eynote: Lord Bethell of Romford (Former Minister for Technology, Innovation and Life Sciences who launched the Government’s Life Sciences Vision)
1?3:55: Panel 1: Hard-wiring Collaboration into the Life Science community in White City
C?hris Williams, PhD (SVP, Corporate Development, Autolus)
Dr Fiona McLaughlin (Chief Scientific Officer, Avacta)
S?teve Bates OBE (CEO, BioIndustry Association)
C?llr. Stephen Cowan (Leader, Hammersmith & Fulham Council)
C?hair: Professor Oscar Ces (Head of Chemistry Department, Imperial College London)
1?4:45: Panel 2: AI for good business: using information better and more responsibly.
P?eter Buckman (Managing Director, Medidata Solutions)
J?ackie Hunter (Board Director, BenevolentAI)
Neil Lawrence (DeepMind Professor of Machine Learning, University of Cambridge)
Anjali Mazumder (AI and Justice & Human Rights Lead, The Alan Turing Institute)
Co-C?hair: Professor Aldo Faisal (Professor of AI & Neuroscience, Imperial College London)
Co-Chair: Prof Sophia Yaliraki (Professor of Theoretical Chemistry, Imperial College London)
1?5:35: Networking break
1?6:00: Panel 3: How do we fund the life sciences? Reflections from investors in the ecosystem
Dr. A?vi Spier (Executive Director, Search & Evaluation, NIBR BD&L, Novartis Institutes for BioMedical Research)
L?eigh Brody, PhD (Investment Manager, Albion VC)
Dr. J?ohn Lee Allen (Managing Partner, RYSE Asset Management)
R?uss Cummings (Chairman, British Patient Capital)
Martin Murphy (CEO and Chair, Syncona Investment Management)
C?hair: Tina Tan (Executive Editor, FirstWord HealthTech)
1?7:00: Networking Reception @Gateway Central, White City Place
1?9:00: END
Avacta Therapeutics’ Chief Scientific Officer Dr Fiona McLaughlin will be an invited speaker at the Jawdrop Life Sciences Summit being held on Thursday 2nd February (12:30pm – 5:30pm) in White City Innovation District.
The theme for this exciting inaugural event is “Breathing life into the life sciences” and Fiona will be joining other distinguished industry and academic leaders as part of the Ecosystem discussion panel. This key session – which is being chaired by Professor Oscar Ces, Imperial College London’s Head of Chemistry – will explore ways of hard-wiring collaboration into the life science community across this emerging global innovation hub.
Organised by Imperial College London and Upstream, the Jawdrop Summit provides a unique opportunity for industry, academia and local government leaders to share insights and key learnings with an audience of world-class scientists, technologists, researchers and decision-makers from across White City and other UK ecosystems.
Tickets are free and available at: https://lnkd.in/eSsAiWuX
Published Jan. 24, 2023
J&J puts focus on cancer drugs in push to reach 2025 sales target
https://www.biopharmadive.com/news/johnson-johnson-cancer-drug-sales-pharma-4q22/641071/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202023-01-25%20BioPharma%20Dive:%20Commercialization%20%5Bissue:47567%5D&utm_term=BioPharma%20Dive:%20Commercialization